Is bio-identical hormone therapy fact or fairy tale?

Nurse Practitioner

Volumn 28, Issue 7, 2003, Pages 39-44

  Francisco, Laura ^a  

^a Penn Avenue Internal Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CONJUGATED ESTROGEN; ESTROGEN; ISOFLAVONE DERIVATIVE; MEDROXYPROGESTERONE ACETATE; PHYTOESTROGEN; PLANT MEDICINAL PRODUCT; PROGESTERONE;

CHEMISTRY; CLIMACTERIUM; DRUG ADMINISTRATION; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; METABOLISM; METHODOLOGY; PHYTOTHERAPY; REVIEW; TREATMENT OUTCOME;

ANDROGENS; CHEMISTRY, PHARMACEUTICAL; CLIMACTERIC; DRUG ADMINISTRATION SCHEDULE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); ESTROGENS, NON-STEROIDAL; FEMALE; HUMANS; ISOFLAVONES; MEDROXYPROGESTERONE 17-ACETATE; PHYTOESTROGENS; PHYTOTHERAPY; PLANT PREPARATIONS; PROGESTERONE; TREATMENT OUTCOME;

EID: 0141923522     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/00006205-200307000-00008     Document Type: Article

References (30)

1. Walker C. BHRT: A natural option for perimenopause and beyond. Advance for Nurse Practitioners 2001; 9(5): 39-45.
2. Lorentzen J. Clinical consideration of HRT. Lecture: Professional Compounding Centers of America. 2001: Houston.
3. Taylor M. Alternatives to conventional HRT. Compr Ther 1997; 23(8): 514-32.
4. Moskowitz D. Changing views: the emergence and efficacy of natural hormones in the treatment of menopause. JAMA 2000; 3(3): 36-44.
5. DeLignieres B, MacGregor E. Risks and benefits of HRT. Cephalagia 2000; 20: 164-9.
6. Lorentzen J. The Evolution of Hormone Treatment. International Journal of Pharmaceutical Compounding 2001; 5(5): 336-8.
7. Hargrove J, Eisenborg E. Menopause. Office Gynecology 1995; 79(6): 1337-56.
8. The writing group for the PEPI trial: Effects of hormone therapy on bone mineral density. Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1996: 276(17): 1389-96.
9. Craven R. Meta-analysis of randomized controlled trails of oestrogen replacement therapy for osteoporosis. Australian and New Zealand Journal of Medicine 2000; 30 (4): 545.
10. Torgeson DJ, Bell-Syer S. Hormone replacement therapy and prevention of non-vertebral fractures: a meta analysis of randomized trials. JAMA 1998; 28 (7): 605-13.
11. Mosca L, Collins P, Herrington DM et al. AHA science advisory: hormone replacement and cardiovascular disease. A statement for healthcare professionals from the AHA. Circulation 2001; 104 (4): 499-503.
12. Follingstad A. Estriol, the forgotten estrogen. JAMA 1978; 239 (1): 29-30.
13. Davis S. The clinical use of androgens in female sexual disorders. Journal of Sex and Marital Therapy 1998; 24: 153-63.
14. Read G, Walker R, Wilson D, Griffiths K. Steroid analysis in the saliva for the assessment of endocrine function. Ann NY Acad Sci 1993: 260-274.
15. Smith K, Judd H. Menopause and postmenopause. In: de Cherney, A. and Pernoll, M. ed. Current Obstetric & Gynecologic Diagnosis & Treatment, 8th edition. New York, NY: McGraw Hill, 1994; 1030-49.
16. Hargrove J, Osteen K. An alternative method of hormone replacement therapy using the natural sex steroids. Infertility and Reproductive Medicine Clinics of North America 1995; 6(4): 653-74.
17. Hargrove J, Maxson W, Wentz A, Bunett L. Menopausal HRT with continous daily oral micronized estradiol and progesterone. Obstetrics and Gynecology 1989; 73 (4): 606-12.
18. Minaguichi H et al. Effects of estriol on bone loss in postmenopausal Japanese women: A multicenter prospective open study. J Obst Gynecol Res 1996; 22 (3): 259-65.
19. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993 Sep 9; 329 (11):802-3.
20. Kirkengen A, Andersen P, Gjersoe E et al. Oestriol in the prophylactic treatment of recurrent urinary tract infections in postmenopausal women. Scand J Prim Health Car 1992 Jun; 10(2): 139-42.
21. Karjalainen A., Heikkinen J, Savolainen M, et al. Metabolic changes induced by peroral oestrogen and transdermal oestradiol gel therapy. British Journal of Obstetrics and Gynecology 1997; 104 (16): 38-43.
22. Anasti J, Leonetti H, Wilson K. Topical progesterone cream has antiproliferative effect on estrogen-stimulated endometrium. Obstet Gynecol 2001 Apr; 97 (4 suppl 1): S10.
23. Leonetti H, Longo S, Anasti J. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999; 94(2): 225-8.
24. Labrie F, Diamond P, Cusan L et al. Effect of 12 month dehydroepiandosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J of Clinical Endrocrinology and Metabolism 1997; 82 (10): 3498-3505.
25. Shifren J, Braunstein G. Simon J et al. Transdermal testosterone treatment in women with impaired sexual function after oopherectomy. N Engl J Med 2000 Sep 7; 343(10): 682-8.
26. Casson P, Elking-Hirsch K., Buster J. et al. Effect of postmenopausal estrogen replacement on circulating androgens (abstract). Obstetrics and Gynecology 1997; 90 (6): 995-8.
27. Algrimm M. Natural hormone replacement: individualized vs one size fits all therapy. Am J Natural Med 1997; 4(7): 6-7.
28. Ouhilal S, Santoro N. Update: Weighing the merits of hormone replacelment. Emergency Medicine 2002; V34 (10): 30-44.
29. Burger H, Dudley E, Jesheng C et al. A prospective longitudinal study of serum testosterone, DHEA, sex hormone binding globulin levels through the menopause transition. J Clin Endrocrinol and Metab 2000; 85(8): 2832-38.
30. Hormone replacement therapy: collaborative decision making and management. Institute for Clinical Systems Improvement (ICSI), Bloomington, MN. Found at. 10/21/02.